Novo Nordisk A S (NONOF) stock

NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO

Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30

$38.24−0.60 (-1.53%)

Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –

Novo Nordisk A S ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was 142.32B DKK, up 4.0% from the year before.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	142.32B DKK	+4.0%
FY2024	Dec 31, 2024	136.88B DKK	+24.6%
FY2023	Dec 31, 2023	109.86B DKK	+35.0%
FY2022	Dec 31, 2022	81.36B DKK	–

Parsed from the XBRL in Novo Nordisk A S's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jan 31, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NONOF.

Revenue growth6.4% · median 8.9%

Gross margin81.0% · median 69.7%

Advertisement
300 × 250

See a number that looks wrong?